This segment focuses on the discovery, development, and commercialization of True Human monoclonal antibodies. XBiotech employs a unique approach to identify and isolate antibodies directly from individuals with natural immunity to specific diseases. Research & Development activities include identifying 'super bloods' with potent antibodies, conducting preclinical studies to validate antibody efficacy and safety, and optimizing antibody production processes. The therapeutic areas targeted include oncology, inflammatory conditions, and infectious diseases. The goal is to develop targeted treatments that improve patient outcomes and quality of life. XBiotech's True Human antibody platform offers a competitive advantage by minimizing immunogenicity and maximizing therapeutic potential. Future opportunities include expanding the pipeline with novel antibodies and securing regulatory approvals for key product candidates.

This segment is dedicated to developing therapies that target interleukin-1 alpha (IL-1α), a potent inflammatory cytokine implicated in various diseases. Research & Development efforts are focused on understanding the role of IL-1α in disease pathogenesis, identifying and validating therapeutic targets, and developing True Human antibodies that specifically block IL-1α activity. The therapeutic areas covered include cancer, stroke, heart attack, and arthritis. The aim is to develop targeted treatments that reduce inflammation, prevent tissue damage, and improve patient outcomes. XBiotech's anti-IL-1α therapies have the potential to address a wide range of medical conditions with significant unmet needs. Future opportunities include expanding clinical trials to new indications and securing partnerships to accelerate commercialization.